Optimizing orthodontic treatment in patients taking bisphosphonates for osteoporosis

American Journal of Orthodontics and Dentofacial Orthopedics

Volumn 135, Issue 3, 2009, Pages 361-374

  Zahrowski, James J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE NECROSIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HALF LIFE TIME; HUMAN; JAW DISEASE; METABOLIC BONE DISEASE; METABOLISM; MIDDLE AGED; OSTEOPOROSIS; OSTEOSCLEROSIS; PANORAMIC RADIOGRAPHY; PERIODONTAL DISEASE; RISK FACTOR; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; FEMALE; HALF-LIFE; HUMANS; JAW DISEASES; MIDDLE AGED; OSTEONECROSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; RADIOGRAPHY, PANORAMIC; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP; TOOTH MOBILITY; TOOTH MOVEMENT; TREATMENT OUTCOME;

EID: 61349189107     PISSN: 08895406     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajodo.2008.08.017     Document Type: Article

References (69)

1. In: Burnham T.H., and Wickersham R.M. (Eds). Drug facts and comparisons. 57th ed (2003), Wolter Kluwer, St Louis 336-349
2. Ukens C. The top 200 brand drugs in 2005. Drug Topics 150 (2006) 25
3. Lindsay R., and Cosman F. Osteoporosis. In: Braunwald E., Hauser S.L., Fauci A.S., Longo D.L., Kasper D.L., and Jameson J.L. (Eds). Harrison's principles of internal medicine. 15th ed (2001), McGraw-Hill, New York 2226-2236
4. Raisz L.G. The osteoporosis revolution. Ann Intern Med 126 (1997) 458-462
5. Rosen C. Postmenopausal osteoporosis. N Engl J Med 353 (2005) 595-603
6. Raisz L.G. Screening for osteoporosis. N Engl J Med 353 (2005) 164-171
7. Khosla S., and Melton L.J. Osteopenia. N Engl J Med 356 (2007) 2293-2300
8. Lin J.H., Russell G., and Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract 101 Suppl (1999) 18-26
9. Watts N.B. Treatment of osteoporosis with bisphosphonates. Endocrinol Metab Clin North Am 27 (1998) 419-439
10. Prescribing information for Boniva, ibandronate intravenous (February 2007), Roche Therapeutics, Nutley, NJ
11. Prescribing information for Reclast, zoledronic acid intravenous (August 2007), Novartis Pharmaceuticals, East Hanover, NJ
12. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 12 Suppl (2000) 2961-2978
13. Licata A.A. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39 (2005) 668-677
14. Masarachia P., Weinreb M., Balena R., and Rodan G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19 (1996) 281-290
15. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9 (2003) 2643-2658
16. Van Beek E.R., Lowik C.W.G.M., and Papapoulos S.E. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates or osteoclast precursors. Bone 30 (2002) 64-70
17. Lin J.H. Bisphosphonates: a review of the pharmacokinetic properties. Bone 18 (1996) 75-85
18. Dixon R.B., Tricker N.D., and Garetto L.P. Bone turnover in elderly canine mandible and tibia. J Dent Res 76 (1997) 336 (IADR abstract 2579)
19. Rodan G., Reszka A., Golub E., and Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20 (2004) 1291-1300
20. Rocha M.L., Malacara J.M., Sanchez-Marin F.J., Vazquez de la Torre C.J., and Fajardo M.E. Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial. J Periodontol 75 (2004) 1579-1585
21. Meunier P.J., Arlot M., Chavassieux P., and Yates J. The effects of alendronate on bone turnover and bone quality. Int J Clin Pract 101 Suppl (1999) 14-17
22. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT research group. J Clin Endocrinol Metab 85 (2000) 4118-4124
23. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., and Quandt S.A. Effects of continuing or stopping alendronate after 5 years of treatment. J Am Med Assoc 296 (2006) 2927-2938
24. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., and Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (2005) 1294-1301
25. Zahrowski J.J. Bisphosphonate treatment: an orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop 131 (2007) 313-322
26. Marx R.E. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws (2007), Quintessence, Hanover Park, Illinois
27. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
28. Igarashi K., Mitani H., Adachi H., and Shinoda H. Anchorage and retentive effects of a bisphosphonate (AHBuBP) on tooth movement in rats. Am J Orthod Dentofacial Orthop 106 (1994) 279-289
29. Rinchuse D.J., Rinchuse D.J., Sosovicka M.F., Robison J.M., and Pendleton R. Orthodontic treatment of patients using bisphosphonates: a report of 2 cases. Am J Orthod Dentofacial Orthop 131 (2007) 321-326
30. Marx R.E. Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
31. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 63 (2005) 682-689
32. AAOMS position paper. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg 65 (2007) 369-376
33. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
34. Guarneri V., Donati S., Nicolini M., Givannelli S., D'Amico R., and Conte P.F. Renal safety and efficacy of I.V. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 10 (2005) 842-848
35. Durie B., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates (letter). New Engl J Med 353 (2005) 99-102
36. Schwarz H.C. Bisphosphonate-associated osteonecrosis of jaws. J Oral Maxillofac Surg 63 (2005) 1555-1556
37. Zahrowski J.J. Comment on the American Association of Oral Maxillofacial Surgeons statement on bisphosphonates. J Oral Maxillofac Surg 65 (2007) 1440-1441
38. Woo S.B., Hellstein J.W., and Kalmar J.R. Systemic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
39. Lomashvili K.A., Cobbs S., Hennigar R.A., Hardcastle K.I., and O'Neill W.C. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 15 (2004) 1392-1401
40. Leu C., Luegmayr E., Freedman L.P., Rodan G.A., and Reszka A.A. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 38 (2006) 628-636
41. Muhlbauer R.C., Bauss F., Schenk R., Janner M., Bosies E., Strein K., et al. BM21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6 (1991) 1003-1011
42. Porras A., Denker A., Santhanagopal A., and Daifotis A.G. Alendronate and risedronate have similar pharmacokinetic half-lives when analyzed over the same time interval. J Bone Miner Res 18 Suppl 2 (2003) S371
43. Prescribing information of Boniva, ibandronate tablets (August 2006), Roche Therapeutics, Nutley, NJ
44. Prescribing information for Actonel, risedronate tablets (April 2008), Proctor & Gamble Pharmaceuticals, North Norwich, NY
45. Wilkinson G.R. Pharmokinetics. In: Hardman J.G., and Limbird L.E. (Eds). Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. (2001), McGraw-Hill, New York 3-29
46. Khan S.A., Kanis J.A., Vasikaran S., Kline W.F., Matuszewski B.K., McCloskey E.V., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12 (1997) 1700-1707
47. Papapoulos S.E., and Cremers S.C. Prolonged bisphosphonate release after treatment in children. N Engl J Med 356 (2007) 1075-1076
48. Prescribing information for Fosamax, alendronate tablets (2006), Merck, Whitehouse Station, NJ
49. Edwards B.J., Hellstein J.W., Jacobsen P.L., Kaltman S., Mariotti A., and Migliorati C.A. ADA report of the Council on Scientific Affairs: dental management of patients receiving oral bisphosphonate therapy-expert panel recommendations. J Am Dent Assoc 137 (2006) 1144-1150
50. Mavrokokki T., Cheng A., Stein B., and Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415-423
51. Sedghizadeh P.P., Stanley K., Caligiuri M., Hofkes S., Lowry B., and Shuler C.F. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw. JADA 140 (2009) 61-66
52. Hess L.M., Jeter J.M., Berham-Hutchins M., and Alberts D.S. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121 (2008) 475-483
53. Schimmer B.P., and Parker K.L. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of andrenocortical hormones. In: Hardman J.G., and Limbird L.E. (Eds). Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed (2001), McGraw-Hill, New York 1649-1677
54. Wood J., Bonjean K., and Ruetz S. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 (2002) 1055-1061
55. Fugazzotto P.A., Lightfoot W.S., Jaffin R., and Kumar A. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and incidence of complications in two private practices. J Periodontol 78 (2007) 1664-1669
56. Jeffcoat M.K. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 21 (2006) 349-353
57. Wang H.L., Weber D., and McCauley L.K. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol 78 (2007) 584-594
58. Starck W.J., and Epker B.N. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 10 (1995) 74-78
59. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
60. Markewicz M.R., Margarone III J.E., Campbell J.H., and Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 136 (2005) 1669-1674
61. van der Pluijm G., Lowik C.W., de Groot H., Alblas M.J., van der Wee-Pals L.J., Bijvoet O.L.M., and Papapoulos S.E. Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants. J Bone Miner Res 6 (1991) 1203-1210
62. Harper R.P., and Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 65 (2007) 573-580
63. Marini J.C. Do bisphosphonates make children's bones better or brittle?. N Engl J Med 349 (2003) 423-426
64. Igarashi K., Adachi H., Mitani H., and Shinoda H. Inhibitory effect of the topical administration of a bisphosphonate (risedronate) on root resorption incident to orthodontic tooth movement in rats. J Dent Res 75 (1996) 1644-1649
65. Sahni M., Guenther H.L., Fleisch H., Collin P., and Martin T.J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91 (1993) 2004-2011
66. Junquera L., and Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?. J Oral Maxillofac Surg 66 (2008) 1516-1517
67. Garcia-Ferrer L., Bagan J.V., Martinez-Sanjuan V., Hernandez-Bazan S., Garcia R., Jimenez-Soriano, et al. MRI of mandibular osteonecrosis secondary to bisphosphonates. Am J Roentgenol 190 (2008) 949-955
68. Mont M.A., Ulrich S.D., Seyler T.M., Smith J.M., Marker D.R., McGrath M.S., et al. Bone scanning of limited value for diagnosis of symptomatic oligofocal and multifocal osteonecrosis. J Rheumatol 35 (2008) 1629-1634
69. Marx R.E., Cillo J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 (2007) 2397-2410